<DOC>
	<DOCNO>NCT03062176</DOCNO>
	<brief_summary>The Interleukin-1 Blockade Treatment Heart Failure Patients End-stage Renal Disease ( End-stage renal disease Heart fAilure - Anakinra Remodeling Trial ) Phase 2 , single-arm trial design estimate effect anakinra , recombinant human Interleukin-1 ( IL-1 ) receptor antagonist , cardiorespiratory fitness patient end-stage renal disease heart failure .</brief_summary>
	<brief_title>Interleukin-1 Blockade Treatment Heart Failure Patients With End-stage Renal Disease ( E-HART )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Written inform consent 18 year old Chronic heart failure Left ventricular ejection fraction le 50 % Creactive protein great equal 2 mg/L Maintenance hemodialysis Inability complete maximal cardiopulmonary exercise test Need urgent emergent care Recent use immunosuppressant , antiinflammatory therapy active rheumatologic disease Allergy rubber , latex , Escherichia coli anakinra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>Interleukin-1</keyword>
	<keyword>Interleukin-1 receptor antagonist</keyword>
	<keyword>Metabolomics</keyword>
	<keyword>Lipidomics</keyword>
</DOC>